KaliVir Immunotherapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate VET3-TGI in Combination with Atezolizumab (Tecentriq®) in Advanced Solid TumorsBusiness Wire • 11/19/25
European Commission approves Roche's Lunsumio subcutaneous for relapsed or refractory follicular lymphomaGlobeNewsWire • 11/19/25
Why biotech and drug stocks are on the mend even though the rest of the market is hurtingMarket Watch • 11/18/25
Genentech's Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast CancerBusiness Wire • 11/18/25
[Ad hoc announcement pursuant to Art. 53 LR] Roche's giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancerGlobeNewsWire • 11/18/25
Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by RochePRNewsWire • 11/12/25
Genentech's Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple SclerosisBusiness Wire • 11/10/25
CellBxHealth jumps 10% after unveiling Roche-linked cancer testing studyProactive Investors • 11/05/25
Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025Business Wire • 11/03/25
Roche to present new data from its broad and innovative haematology portfolio at ASH 2025GlobeNewsWire • 11/03/25
Manifold Bio Announces Strategic Collaboration with Roche to Develop Multiple Next-Generation Brain Shuttles for Neurological DiseasesBusiness Wire • 11/03/25
Positive phase III data for Roche's Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosusGlobeNewsWire • 11/03/25
Positive Phase III Data for Genentech's Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus ErythematosusBusiness Wire • 11/03/25
Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengueGlobeNewsWire • 10/29/25
Positive Phase III Results for Genentech's Gazyva in Children and Young Adults With Idiopathic Nephrotic SyndromeBusiness Wire • 10/28/25